These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 27029284)
21. Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practice. Kovacic JC; Lee P; Karajgikar R; Baber U; Narechania B; Suleman J; Moreno PR; Sharma SK; Kini AS J Interv Cardiol; 2012 Oct; 25(5):482-92. PubMed ID: 22724441 [TBL] [Abstract][Full Text] [Related]
22. Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients. Yang TH; Kim DI; Kim DK; Jang JS; Kim U; Seol SH; Kim DK; Hong GR; Park JS; Shin DG; Kim YJ; Cho YK; Nam CW; Hur SH; Kim KB; Kim DS Korean J Intern Med; 2011 Jun; 26(2):145-52. PubMed ID: 21716590 [TBL] [Abstract][Full Text] [Related]
23. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). Yu J; Mehran R; Baber U; Ooi SY; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Maehara A; Xu K; Ben-Yehuda O; Kirtane AJ; Stone GW Circ Cardiovasc Interv; 2017 Feb; 10(2):. PubMed ID: 28193677 [TBL] [Abstract][Full Text] [Related]
24. Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). Campo G; Tebaldi M; Vranckx P; Biscaglia S; Tumscitz C; Ferrari R; Valgimigli M J Am Coll Cardiol; 2014 Feb; 63(6):506-12. PubMed ID: 24161321 [TBL] [Abstract][Full Text] [Related]
25. Dual antiplatelet therapy in patients with a long coronary artery lesion over 30 mm: Determinants and impact on prognosis. Manchuelle A; Delhaye C; Schurtz G; Sudre A; Hurt C; Bonello L; Puymirat E; Bauters C; Lemesle G Arch Cardiovasc Dis; 2015 Apr; 108(4):235-43. PubMed ID: 25682548 [TBL] [Abstract][Full Text] [Related]
26. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. Valgimigli M; Patialiakas A; Thury A; McFadden E; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Airoldi F; Ferlini M; Liistro F; Dellavalle A; Vranckx P; Briguori C; J Am Coll Cardiol; 2015 Mar; 65(8):805-815. PubMed ID: 25720624 [TBL] [Abstract][Full Text] [Related]
27. Comparison of the antiplatelet effect of clopidogrel hydrogenosulfate and clopidogrel besylate in patients with stable coronary artery disease. Hamilos M; Saloustros I; Skalidis E; Igoumenidis N; Kambouris M; Chlouverakis G; Vougia D; Loggakis I; Vardas PE; Kochiadakis G J Thromb Thrombolysis; 2015 Oct; 40(3):288-93. PubMed ID: 25662861 [TBL] [Abstract][Full Text] [Related]
28. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial. Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058 [TBL] [Abstract][Full Text] [Related]
29. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963 [TBL] [Abstract][Full Text] [Related]
30. Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. Bundhun PK; Qin T; Chen MH BMC Cardiovasc Disord; 2015 Oct; 15():118. PubMed ID: 26450578 [TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. Capranzano P; Ferreiro JL; Ueno M; Capodanno D; Dharmashankar K; Darlington A; Desai B; Tello-Montoliu A; Rollini F; Angiolillo DJ Catheter Cardiovasc Interv; 2013 Jan; 81(1):42-9. PubMed ID: 22431415 [TBL] [Abstract][Full Text] [Related]
32. Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials. Pandit A; Giri S; Hakim FA; Fortuin FD Catheter Cardiovasc Interv; 2015 Jan; 85(1):34-40. PubMed ID: 24753084 [TBL] [Abstract][Full Text] [Related]
33. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study. Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G; Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063 [TBL] [Abstract][Full Text] [Related]
34. Determination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests. Woo KS; Kim BR; Kim JE; Goh RY; Yu LH; Kim MH; Han JY Korean J Lab Med; 2010 Oct; 30(5):460-8. PubMed ID: 20890076 [TBL] [Abstract][Full Text] [Related]
35. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. Musumeci G; Rossini R; Lettieri C; Capodanno D; Romano M; Rosiello R; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ Catheter Cardiovasc Interv; 2012 Sep; 80(3):395-405. PubMed ID: 22109961 [TBL] [Abstract][Full Text] [Related]
37. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Hahn JY; Song YB; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Kim J; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC; Lancet; 2018 Mar; 391(10127):1274-1284. PubMed ID: 29544699 [TBL] [Abstract][Full Text] [Related]
38. Mortality and cancer after 12 versus 30 months dual antiplatelet therapy. The Korean Outcomes Registry Evaluating Antithrombotics (KOREA). Serebruany VL; Kim MH; Cabrera-Fuentes HA; Lee K; Cho YR; Park K; Park TH; Kim YD; Yoon SC Thromb Haemost; 2017 May; 117(5):934-939. PubMed ID: 28251238 [TBL] [Abstract][Full Text] [Related]
39. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Lee CW; Ahn JM; Park DW; Kang SJ; Lee SW; Kim YH; Park SW; Han S; Lee SG; Seong IW; Rha SW; Jeong MH; Lim DS; Yoon JH; Hur SH; Choi YS; Yang JY; Lee NH; Kim HS; Lee BK; Kim KS; Lee SU; Chae JK; Cheong SS; Suh IW; Park HS; Nah DY; Jeon DS; Seung KB; Lee K; Jang JS; Park SJ Circulation; 2014 Jan; 129(3):304-12. PubMed ID: 24097439 [TBL] [Abstract][Full Text] [Related]
40. Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Ueno M; Ferreiro JL; Tomasello SD; Tello-Montoliu A; Capodanno D; Seecheran N; Kodali M; Dharmashankar K; Desai B; Charlton RK; Bass TA; Angiolillo DJ JACC Cardiovasc Interv; 2011 Aug; 4(8):905-12. PubMed ID: 21851906 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]